Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information

Beta 2 Microglobulin (B2M) Tumor Marker Test: MedlinePlus Lab Test Information

What is a beta-2 microglobulin tumor marker test?

This test measures the amount of a protein called beta-2 microglobulin (B2M) in the blood, urine, or cerebrospinal fluid (CSF). B2M is a type of tumor marker. Tumor markers are substances made by cancer cells or by normal cells in response to cancer in the body.

B2M is found on the surface of many cells and is released into the body. Healthy people have small amounts of B2M in their blood and urine.

  • People with cancers of the bone marrow and blood often have high levels of B2M in their blood or urine. These cancers include multiple myeloma, lymphoma, and leukemia.
  • High levels of B2M in cerebrospinal fluid can mean that cancer has spread to the brain and/or spinal cord.

A B2M tumor marker test is not used to diagnose cancer. But it can provide important information about your cancer, including how serious it is and how it may develop in the future.

Other names: total beta-2 microglobulin, β2-microglobulin, B2M

What is it used for?

A beta-2 microglobulin tumor marker test is most often given to people who have been diagnosed with certain cancers of the bone marrow or blood. The test may be used to:

  • Figure out the severity of cancer and whether it has spread. This process is known as cancer staging. The higher the stage, the more advanced the cancer is.
  • Predict disease development and guide treatment.
  • See if cancer treatment is effective.
  • See if cancer has spread to the brain and spinal cord.

Why do I need a beta-2 microglobulin tumor marker test?

You may need this test if you have been diagnosed with multiple myeloma, lymphoma, or leukemia. The test can show the stage of your cancer and whether your cancer treatment is working.

What happens during a beta-2 microglobulin tumor marker test?

A beta-2 microglobulin test is usually a blood test, but may also be given as a 24-hour urine test, or as a cerebrospinal fluid (CSF) analysis.

For a blood test, a health care professional will take a blood sample from a vein in your arm, using a small needle. After the needle is inserted, a small amount of blood will be collected into a test tube or vial. You may feel a little sting when the needle goes in or out. This usually takes less than five minutes.

For a 24-hour urine sample, your health care provider or a laboratory professional will give you a container to collect your urine and instructions on how to collect and store your samples. A 24-hour urine sample test usually includes the following steps:

  • Empty your bladder in the morning and flush that urine away. Record the time.
  • For the next 24 hours, save all your urine in the container provided.
  • Store your urine container in the refrigerator or a cooler with ice.
  • Return the sample container to your health provider’s office or the laboratory as instructed.

For a cerebrospinal fluid (CSF) analysis, a sample of spinal fluid will be collected in a procedure called a spinal tap (also known as a lumbar puncture). A spinal tap is usually done in a hospital. During the procedure:

  • You will lie on your side or sit on an exam table.
  • A health care provider will clean your back and inject an anesthetic into your skin, so you won’t feel pain during the procedure. Your provider may put a numbing cream on your back before this injection.
  • Once the area on your back is completely numb, your provider will insert a thin, hollow needle between two vertebrae in your lower spine. Vertebrae are the small backbones that make up your spine.
  • Your provider will withdraw a small amount of cerebrospinal fluid for testing. This will take about five minutes.
  • You’ll need to stay very still while the fluid is being withdrawn.
  • Your provider may ask you to lie on your back for an hour or two after the procedure. This may prevent you from getting a headache afterward.

Will I need to do anything to prepare for the test?

You don’t need any special preparations for a blood or urine test.

You don’t need any special preparations for a CSF analysis, but you may be asked to empty your bladder and bowels before the test.

Are there any risks to the test?

There is very little risk to having a blood or urine test. After a blood test, you may have slight pain or bruising at the spot where the needle was put in, but most symptoms go away quickly.

There is very little risk to having a spinal tap. You may feel a little pinch or pressure when the needle is inserted. After the test, you may get a headache, called a post-lumbar headache. About one in ten people will get a post-lumbar headache. This can last for several hours or up to a week or more. If you have a headache that lasts longer than several hours, talk to your health care provider. He or she may be able to provide treatment to relieve the pain. You may feel some pain or tenderness in your back at the site where the needle was inserted. You may also have some bleeding at the site.

What do the results mean?

If the test was used to find out how advanced your cancer is (cancer stage), the results may show how much cancer is in your body and whether it is likely to spread.

If the B2M test was used to check how well your treatment is working, your results may show:

  • Your B2M levels are increasing. This may mean your cancer is spreading, and/or your treatment is not working.
  • Your B2M levels are decreasing. This may mean your treatment is working.
  • Your B2M levels have not increased or decreased. This may mean your disease is stable.
  • Your B2M levels decreased, but then later increased. This may mean your cancer has come back after you’ve been treated.

If you have questions about your results, talk to your health care provider.

Is there anything else I need to know about a beta-2 microglobulin tumor marker test?

Beta-2 microglobulin tests are not always used as tumor marker tests for cancer patients. B2M levels are sometimes measured to:

  • Check for kidney damage in people with kidney disease.
  • Find out if a viral infection, such as HIV/AIDS, has affected the brain and/or spinal cord.
  • Check to see if disease has advanced in people with multiple sclerosis, a chronic disease affecting the brain and spinal cord.
Tagged with:

About author

Related Articles